Page 17 - Safety Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

>> reporter: and taken hold, it has. sherry tenpenny's conspiracy theories have spread far and wide. >> my own doctor tried to get me to get the shot and i told him to go watch dr. tenpenny. >> so you trust this woman on the internet? more than your own doctor some. >> uh-huh. i do. >> another superspreader of covid misinformation only banned by youtube this week, joseph mercola, who had almost half a million followers on the platform. >> it's an unproved vaccine. it's just being accelerated, eliminate virtually every safety study. >> reporter: he still has almost 2 million followers on facebo...

I guess the question that i have for you is do you have the same discomfort i do that i could get a booster shot before any child under 12, when kids under 12 can't get it. does it make you as uncomfortable as it makes me? >> no, joy, it doesn't because we have to finish the clinical trials to show that in children that young, it's safe and induces the kind of response that you would predict would be protective. we already know from clinical trials that in adults like yourself that the vaccine, whichever you got, either moderna or pfizer or j&j is safe and effective. i think that's apples and ...

Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights - read this article along with other careers information, tips and advice on BioSpace

The company reported that cash on hand increased 57% year-over-year from $59.2 million to $93.1 million The RECONNECT trial, planned for the third quarter, will enroll around 200 children and adolescents with Fragile X Syndrome Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) (FRA:6ZY) told investors it believes it has sufficient cash to fund its operations well into the first half of 2024 after the company reported cash and equivalents of $93.1 million on hand at the end of the first quarter.  In a business update for the three months ended March 31, the company reported that cash on h...

Zynerba receives FDA guidance on confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome The RECONNECT trial of the transdermal get is designed to evaluate its efficacy and safety in children and adolescents with FXS The company believes that the results, if positive, from RECONNECT will be sufficient to support the submission of a New Drug Application for Zygel Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has received guidance from the US Food and Drug Administration (FDA) on a confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome (FXS).  The trial...